个人癌症高级基因组学领导者的个人Interian，Inc。宣布发行与其行业领先的最小残留疾病（MRD）和复发平台有关的美国关键专利，下一个个人。

The patent, US Patent No. 11,299,783, entitled “Methods and Systems for Genetic Analysis,” was issued on April 12, 2022. The ‘783 patent claims novel methods for a partially personalized assay, combining both tumor-informed and prespecified (tumor naïve) content. Tumor-informed methods can provide high sensitivity for detection of MRD. They can also support tracking of variants specific to an individual patient’s cancer, such as those targeted by specific therapies or which are thought to elicit an immune response. Prespecified, tumor-naïve content can include variants not detected on initial sequencing of a tumor, but which may emerge and confer drug resistance as a tumor evolves. It can also include driver mutations of a second primary tumor, which may arise independently during the course of the initial cancer. The ‘783 patent is a member of a patent family that broadly describes Personalis’ foundational work relating to the development of personalized assays for disease identification and tracking.

“个人”最近推出了下一个个人平台利用了783专利的许多元素。在MRD测定中，它是独一无二的，它结合了对肿瘤负担的高度敏感测量以及在单个面板设计中同时跟踪数千种肿瘤变体的肿瘤变体。

“ 783专利”的发行增加了人格化的知识产权组合，其中包括与个性化基因测试有关的多个早期家庭。总体而言，个人派有19项发行了我们和外国专利，涵盖了16个不同的家庭，与先进的基因组测序和分析解决方案有关。此外，该公司已有25多个待定的美国和外国专利申请与其现有的高级癌症检测平台和新型研究领域有关，包括解释其平台生成的遗传数据的方法。

“癌症非常复杂且充满活力，”个人活动首席执行官兼联合创始人约翰·韦斯特（John West）说。“我们的下一个个人方法结合了单个集成数据流中患者肿瘤的检测，定量和详细表征。随着DNA测序和DNA合成的成本和周转时间迅速改善，敏感和详细的监测对患者的整个临床轨迹变得负担得起，我们相信它将成为新的护理标准。”